Natera to Present Update About Development, Commercialization of Non-Invasive Prenatal Diagnostic Test at the Citi 2012 Global Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb 24, 2012-- Natera, formerly known as Gene Security Network, today announced that the company is scheduled to present at the Citi 2012 Global Health Care Conference at 4 p.m. EST on Monday, February 27, 2012, at the Waldorf Astoria in New York City. Matthew Rabinowitz, Ph.D., Natera's chief executive officer, will provide an overview of the company and an update on its reproductive genetic testing services.
"Our non-invasive prenatal diagnostic test is moving rapidly through development, including an NIH-funded clinical investigation, toward global commercialization later this year," said Rabinowitz. "We look forward to presenting at this conference and providing background about how our test will be able to deliver highly accurate results for detection of multiple conditions, including trisomy 13, 18 and 21, as well as certain sex chromosome abnormalities." About Natera Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA - as small as that from a single cell.
Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of reproductive genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother's blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.
CONTACT: Russo Partners Ian Stone, 619-308-6540 email@example.com Lena Evans, 212-845-4262 firstname.lastname@example.org or Natera, Inc.
Jennifer Keller, 650-249-9090 ext. 309 email@example.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS BABY/MATERNITY CONSUMER SOURCE: Natera Copyright Business Wire 2012 PUB: 02/24/2012 08:00 AM/DISC: 02/24/2012 08:00 AM http://www.businesswire.com/news/home/20120224005168/